Zheng Quan Shi Bao Wang·2025-07-07 09:55Market Performance - The Sci-Tech Innovation Board (STAR Market) index fell by 0.66%, closing at 978.29 points, with a total trading volume of 2.401 billion shares and a turnover of 81.468 billion yuan, resulting in a weighted average turnover rate of 1.35% [1] - Among the tradable stocks on the STAR Market, 281 stocks closed higher, with 3 stocks rising over 10% and 17 stocks rising between 5% and 10%. Conversely, 292 stocks closed lower, with 2 stocks declining over 10% [1] Turnover Rate Analysis - The turnover rate distribution shows that 2 stocks had a turnover rate exceeding 20%, 10 stocks had a turnover rate between 10% and 20%, and 28 stocks had a turnover rate between 5% and 10%. Additionally, 76 stocks had a turnover rate between 3% and 5%, while 270 stocks had a turnover rate between 1% and 3%, and 202 stocks had a turnover rate below 1% [1] - The stock with the highest turnover rate was Jin Chengzi, which closed up by 15.37% with a turnover rate of 32.88% and a transaction amount of 397 million yuan. Other notable stocks included Si Kan Technology, which rose by 13.81% with a turnover rate of 26.69% and a transaction amount of 405 million yuan [1] Sector Performance - In terms of sector performance, the pharmaceutical and biotechnology sector had the highest representation among stocks with a turnover rate exceeding 5%, with 10 stocks listed. The electronics and power equipment sectors followed, with 7 and 5 stocks, respectively [2] Capital Flow - Among high turnover stocks, 21 stocks experienced net inflows of main funds, with significant net inflows seen in Changyang Technology, Si Kan Technology, and South Network Technology, amounting to 45.33 million yuan, 42.70 million yuan, and 39.75 million yuan, respectively. Conversely, stocks like Kexing Pharmaceutical, Youfang Technology, and Rongchang Biology saw significant net outflows, with amounts of 116 million yuan, 62.64 million yuan, and 31.08 million yuan, respectively [2] - Recent trends in leveraged funds indicated that 30 stocks received net purchases of leveraged funds, with Kexing Pharmaceutical, Weixin Biotechnology, and Huiyu Pharmaceutical showing the largest increases in financing balances, amounting to 117 million yuan, 88.84 million yuan, and 56.62 million yuan, respectively. In contrast, stocks like Rongchang Biology, Liyang Chip, and Xinpengwei saw significant decreases in financing balances [2]